HealthEquity, Inc.
HQYHealthEquity is a provider of technology-enabled services that administers health savings accounts (HSAs) and other consumer-directed benefits.
As a leading HSA custodian, its core identity revolves around connecting individuals, employers, and financial partners to optimize healthcare savings and spending.
Updated: February 19, 2026, 16:00 EST
Investment Opinion: Should I buy HQY Today?
Based on the comprehensive analysis of HQY, the stock is not worth buying at the current juncture. It carries significant risks that outweigh its limited strengths.
Technical Analysis & Risk: HQY is in a pronounced downtrend, having fallen sharply and now trading near its 52-week low. This steep decline, coupled with a substantial maximum drawdown of over 35%, indicates severe bearish momentum and high volatility risk despite its low beta. Attempting to catch this falling knife is speculative and carries a high probability of further losses.
Fundamentals & Valuation: While the company maintains strong profitability and a healthy balance sheet, its margins are compressing, and operational efficiency is weak. More critically, the stock is richly valued with a high forward P/E and elevated EV/EBITDA, a premium that appears unjustified given the negative earnings growth.
Overall Recommendation: A buy recommendation is not warranted. Investors should avoid HQY due to its strong negative price momentum, high idiosyncratic risk, and premium valuation that is difficult to support with the current deteriorating fundamentals. Any potential recovery would require a clear reversal in both technical trends and business performance, which is not currently evident.
*Note: This is not investment advice, for reference only.*
HQY 12-Month Price Forecast
RockFlow Model Forecast: Three Scenarios for 2026
Based on the provided analysis, the 12-month outlook for HQY is bearish. The primary catalysts for any potential recovery would be a clear reversal of the negative earnings trend and a breakout above key technical resistance levels, though neither is currently evident. The significant risks are predominant, including the strong downtrend, deteriorating fundamentals with compressing margins, and a premium valuation that appears unjustified. In the absence of analyst targets, the current price action and negative momentum suggest the stock is likely to remain under pressure or trade lower, potentially testing or breaking below its 52-week lows.
Wall Street Consensus
Most Wall Street analysts are optimistic about HealthEquity, Inc.'s 12-month outlook, with consensus target around $78.88, indicating expected upside potential.
Bulls vs Bears: HQY Investment Factors
Overall, HQY has investment potential but also faces challenges. Here are key factors to weigh before investing.
Bullish
- Strong Q3 Earnings Beat: Earnings and revenue exceeded estimates, driven by HSA growth and improved margins.
- Record HSA Growth: HSA assets surged 26% year-over-year, reaching $36.5 billion with 10.6 million accounts.
- Analyst Price Target Upside: Some analysts see potential 61-65% upside from current share price valuation.
Bearish
- Institutional Selling Pressure: Ranger Investment cut its holdings in HQY by 31.7% last quarter.
- Lowered Price Target: BTIG maintained a Buy rating but reduced its price target by over 15%.
- Market Perform Rating: BMO Capital reiterated a Market Perform rating despite strong results.
HQY Technical Analysis
HQY has demonstrated sharply deteriorating performance, declining substantially across all measured timeframes significantly underperforming the broader market.
The stock has experienced steep declines of over 14% in one month and 25% over three months, severely underperforming the market by a similar magnitude (-25.49% relative weakness) despite its low beta suggesting it should exhibit less volatility than the market.
Currently trading at $74.36, HQY sits just 2.2% above its 52-week low of $72.76, having fallen over 36% from its 52-week high; this proximity to the recent low, combined with the substantial maximum drawdown of -35.66%, indicates the stock is deeply oversold.
| Period | HQY Return | S&P 500 |
|---|---|---|
| 1m | -6.1% | +1.0% |
| 3m | -20.7% | +1.9% |
| 6m | -15.2% | +6.5% |
| 1y | -29.4% | +12.1% |
| ytd | -13.4% | +0.2% |
HQY Fundamental Analysis
Revenue & Profitability: Headquarters (HQY) experienced a slight sequential revenue decline to $322 million in Q3 2026 but maintains strong profitability, with a robust gross profit margin of 62.4%. However, operating and net income margins decreased from the prior quarter to 24.8% and 16.0% respectively, indicating rising operating expenses that compressed profitability.
Financial Health: The company exhibits exceptional liquidity with a current ratio of 4.13 and holds substantial cash reserves. While the debt-to-equity ratio of 0.48 indicates moderate leverage, the cash flow to debt ratio of 0.13 suggests that operating cash flow coverage of outstanding debt is relatively low.
Operational Efficiency: HQY demonstrates moderate efficiency with a return on equity of 2.4% and an asset turnover of 0.09, reflecting challenges in generating revenue from its asset base. The operating cash flow to sales ratio of 43% is healthy, indicating efficient conversion of revenue into cash, supported by a strong cash conversion cycle of 16.5 days.
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
RockFlow Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
Try Now & Get Tesla Stock RewardValuation Analysis: Is HQY Overvalued?
Valuation Level: HQY appears richly valued based on key metrics. The forward PE ratio of approximately 39.3 is significantly higher than the TTM PE of 32.9, indicating growth expectations are already priced in. The elevated EV/EBITDA of 73.5 and negative PEG ratio due to negative earnings growth further suggest the stock trades at a premium valuation that may not be fully justified by current fundamentals.
Peer Comparison: Without specific industry average data, a precise peer comparison cannot be made. However, the metrics presented—particularly the high PE ratios and EV/EBITDA—typically indicate a premium valuation relative to broader market averages. This suggests HQY trades at valuation levels that would likely exceed most value-oriented industry benchmarks, though healthcare services or consumer discretionary sector averages would provide more meaningful context.
Investment Risk Disclosure
Volatility Risk: HQY exhibits exceptionally low market sensitivity with a Beta of 0.244, suggesting its price movements are largely independent of broader market swings. However, this low correlation to the market did not prevent a significant 1-year maximum drawdown of -35.66%, indicating the stock carries substantial idiosyncratic risk that can lead to sharp, isolated price declines.
Other Risks: The notable absence of reported short interest implies that professional investors do not perceive HQY as significantly overvalued or facing severe fundamental headwinds. Nevertheless, the extreme volatility evidenced by the drawdown, potentially combined with liquidity risks if trading volume is low, represents the primary concern beyond direct market correlation.
FAQs
Based on the analysis, my view is neutral to cautiously bullish.
The stock appears richly valued and has experienced significant technical deterioration, but it possesses strong fundamentals, record HSA growth, and unanimous "Buy" ratings from analysts, suggesting long-term potential. However, recent selling pressure and compressed margins are near-term headwinds.
This stock is suitable for patient, long-term investors who are comfortable with volatility and believe in the company's fundamental growth story, rather than investors seeking a quick turnaround or deep value.
Based on the provided data, HQY stock appears to be overvalued. Key valuation metrics like its forward P/E of 39.3 and a notably high EV/EBITDA of 73.5 suggest a significant premium. This is further supported by a negative PEG ratio, indicating that the market's high growth expectations are not backed by positive earnings growth. While the company has strong profitability and liquidity, these fundamentals do not seem to justify its current lofty valuation levels, which are well above typical market averages.
Based on the provided information, here are the key risks of holding HQY stock, ordered by importance:
1. Severe Idiosyncratic Price Decline Risk: The stock carries substantial company-specific risk, evidenced by a severe -35.66% maximum drawdown and steep recent declines, despite its low correlation to the overall market. 2. Operational Efficiency and Profitability Compression Risk: The company faces challenges in generating returns from its assets (low ROE and asset turnover) and is experiencing rising operating expenses that are compressing its net income margins. 3. Weak Cash Flow Relative to Debt Obligations Risk: Despite moderate leverage, the low cash flow to debt ratio of 0.13 indicates a limited ability to cover outstanding debt obligations from its current operating cash flow.
Based on the provided analysis, my 2026 forecast for HQY remains cautious. For a base case, I anticipate a target range of $60-$70, reflecting continued pressure from rising expenses and operational inefficiencies, while a bull case of $80-$90 would require a successful reversal of the negative margin trend and improved asset turnover. Key growth drivers are the company's strong liquidity, healthy cash conversion cycle, and robust gross margins, but these are currently offset by compressing profitability and low returns. My main assumptions are that operating expenses remain a headwind and the premium valuation is unsustainable without fundamental improvement. This forecast is highly uncertain, as the lack of analyst consensus and the stock's negative momentum suggest significant downside risk if current trends persist.